Market Intelligence, Clinical Progress, and High-Purity Reagents for PCOS and Reproductive Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AMH (Anti-Müllerian Hormone) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Ligand) | AMH Recombinant Protein (Pro/Latent & Mature Forms) High purity (>95%), HEK293 Expressed (Native Glycosylation), Endotoxin <1EU/μg. Sequence Verified. |
View AMH Products |
| Antigen (Receptor) | AMHR2 ECD-Fc Fusion Protein Extracellular domain for binding studies. Theoretical MW verified. |
View AMHR2 Products |
| Gene Delivery | AMHR2 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves native conformation for binding assays. |
View AMHR2 Products |
| Co-Receptor | ALK2 (BMPR1A) Recombinant Protein Type I receptor component. Required for ternary complex formation assays. |
View ALK2 Products |
| Benchmark Control | Anti-AMH Neutralizing Antibody (Reference Sequence) Recombinant positive control for activity inhibition studies. |
View AMH Products |
| Validation Tool | AMHR2 siRNA Set For receptor knockdown and specificity verification. |
View AMHR2 Products |
| Related Target | FSHR (Follicle Stimulating Hormone Receptor) Functional antagonist pathway; critical for folliculogenesis combination studies. |
View FSHR Products |
| Related Target | ALK3 (BMPR1B) Alternative type I receptor for AMH signaling; cross-talk validation. |
View ALK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Latent vs. Active Conformational Discrimination | AMH Pro-domain (Latent) and Cleaved Mature forms available separately; Sequence-verified cleavage sites |
| AMHR2 Membrane Topology Preservation | Lentivirus-delivered full-length AMHR2 for stable cell lines; Maintains physiological glycosylation and dimerization |
| Type I/II Receptor Ternary Complex Assembly | ALK2 & ALK3 co-receptor proteins available for SPR/Biolayer interferometry studies |
| Species Translation (Mouse to Human) | Human/Mouse/Cyno ortholog panel with prodomain cleavage site homology mapping |
| False Positive Screening | Validated siRNA controls included; AMH-null protein background available |
Live AMH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of AMH signaling represents a paradigm shift in reproductive endocrinology. While historically utilized as a diagnostic biomarker for ovarian reserve, AMH is now positioned as a direct therapeutic target for Polycystic Ovary Syndrome (PCOS) and fertility preservation. The competitive landscape is dominated by small molecule and biologic antagonists against the AMH receptor (AMHR2), aiming to reverse the pathological follicular arrest characteristic of PCOS. As first-generation AMHR2 antagonists (led by Oviva Therapeutics and academic consortia) enter preclinical development, the R&D focus is shifting toward combination strategies with FSH sensitization and long-acting injectable formulations. The next wave of innovation targets allosteric modulation of the AMH signaling complex to preserve tissue specificity while avoiding complete pathway ablation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Oviva Therapeutics, Academic Labs | PCOS, Infertility | AMHR2/ALK2 Ternary Complex Binding (Need full-length receptor presentation via lentivirus) |
| Peptide Inhibitor | Merck (exploratory) | Ovarian Hyperstimulation | Latent AMH Processing Assay (Need uncleavable AMH mutant controls) |
| Biomarker Diagnostic | Beckman Coulter, Roche | Ovarian Reserve | Standard Curve Antigens (Need glycosylation-matched recombinant AMH) |
| Gene Therapy | Early Stage Startups | Primary Ovarian Insufficiency | Functional Validation (Need AMH overexpression lentivirus & knockdown siRNA) |
Key Mutations and Functional Domains
Based on UniProt P03971, key mutations in AMH include:
- rs149082963 (in PMDS1): Associated with persistent Müllerian duct syndrome.
- rs10407022: A common variant with potential functional impact.
- VAR_007485 (in PMDS1): Another mutation linked to PMDS1.
These mutations highlight the importance of sequence-verified reagents for accurate functional studies.
Molecular Differentiation & Assay Strategy
AMH Ligand Complexity (Latent vs Active)
AMH is secreted as a pro-hormone (Pro-AMH) and requires proteolytic cleavage (by BMP1/PCP family enzymes) to release the C-terminal mature dimer for biological activity. Therapeutic interventions must target:
- Latent form: For diagnostic standards (requires intact glycosylation).
- Active form: For receptor binding assays.
- Cleavage site mutants (e.g., R454A): Uncleavable latent form as competitive inhibitor tool.
Receptor Complex Assembly
AMH signaling requires AMHR2 (type II receptor) and type I receptor (ALK2 or ALK3) to form a heterotetramer. Successful drug development must assess:
- Binary interaction (AMH-AMHR2)
- Ternary complex stability (AMH-AMHR2-ALK2)
Species Differences
Human and mouse AMH differ in prodomain cleavage efficiency and glycosylation patterns. Preclinical validation for PCOS drugs must rely on humanized AMH/AMHR2 systems rather than solely on mouse primary cells.
Assay Design Recommendations
- Ternary Complex SPR/BLI: Detect disruption of AMHR2-ALK2 interaction (allosteric inhibition) or direct blocking of AMH binding (orthosteric inhibition). TarMart provides AMHR2-ECD-Fc and ALK2-ECD protein pairs.
- Cell-based SMAD Reporter Assay: Use full-length AMHR2 lentivirus to construct stable cell lines for measuring SMAD1/5/8 phosphorylation.
- Latent Processing Inhibition: Use wild-type AMH (cleavable) and R454A mutant (uncleavable) as positive and negative controls.
- Cross-reactivity Panel: Exclude cross-inhibition of BMPR-II using BMPR-II ECD protein.
TarMart Product Strategy
Core Product Lines
- AMH Dual-Form Protein System: Both Pro-domain intact Latent form and purified Mature C-terminal dimer for full R&D chain.
- AMHR2 Membrane Display System: Lentivirus carrying full-length AMHR2 for correct glycosylation and dimerization, suitable for HTS and affinity ranking.
- Receptor Complex Components: ALK2 and ALK3 recombinant proteins for ternary complex assembly studies.
Differentiation
- Sequence-verified cleavage sites to avoid batch-to-batch activity variability.
- Physiological glycosylation via HEK293 expression system.
- Functional controls (siRNA, overexpression plasmids) for closed-loop target validation.
Cross-Selling Targets
- AMHR2: Core receptor, essential for all functional experiments.
- ALK2 (BMPR1A): Type I co-receptor for ternary complex studies.
- FSHR: Key control for downstream effects after AMH inhibition.
- BMP15/GDF9: For off-target screening in ovarian TGF-β family.